keyword
MENU ▼
Read by QxMD icon Read
search

Mitroflow

keyword
https://www.readbyqxmd.com/read/29100646/an-unexpected-risk-factor-for-early-structural-deterioration-of-biological-aortic-valve-prostheses
#1
Carlo Bassano, Valentina Gislao, Emanuele Bovio, Sonia Melino, Ilaria Tropea, Guglielmo Saitto, Marta Pugliese, Dionisio F Colella, Antonio Scafuri, Giovanni Ruvolo
BACKGROUND: An alarming rate of early failure has been recently reported for the LivaNova (previously Sorin) Mitroflow (LivaNova, London, UK) bioprosthesis. Here, we aimed at verifying if this possible underperformance is confirmed in a large, single-center experience and identifying the risk factors associated with early deterioration. METHODS: In all, 459 Mitroflow valves have been implanted from July 2009 to December 2013 (patients' mean age 73 years; 204 women)...
November 1, 2017: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/29029140/structural-valve-deterioration-in-the-mitroflow-biological-heart-valve-prosthesis
#2
Issa Farah Issa, Steen Hvitfeldt Poulsen, Farhad Waziri, Christian Torp Pedersen, Per Hostrup Nielsen, Lars Riber, Jordi S Dahl, Peter Søgaard, Martin Agge Nørgaard, Jacob Eifer Møller
OBJECTIVES: Concern has been raised regarding the long-term durability of the Mitroflow biological heart valve prosthesis. Our aim was to assess the incidence of structural valve degeneration (SVD) for the Mitroflow bioprosthesis in a nationwide study in Denmark including all patients alive in Denmark who had received a Mitroflow aortic bioprosthesis since 2000. METHODS: Patients alive in Denmark with a Mitroflow bioprosthesis implanted since January 2000 were invited to participate in a nationwide cross-sectional study with a predefined definition of SVD...
September 28, 2017: European Journal of Cardio-thoracic Surgery
https://www.readbyqxmd.com/read/28964416/the-prevalence-of-patient-prosthesis-mismatch-can-be-reduced-using-the-trifecta-aortic-prosthesis
#3
Daniel Hernandez-Vaquero, Rocio Diaz, Isaac Pascual, Jose Rozado, Jesus M De la Hera, Victor Leon, Pablo Avanzas, Maria Martín, Daniel García-Iglesias, David Calvo, Jacobo Silva, César Moris
BACKGROUND: Some important studies have shown that patient-prosthesis mismatch is a frequent occurrence after surgical aortic valve replacement that impairs survival. The Trifecta valve (St. Jude Medical Inc, St. Paul, MN) has special architecture designed to achieve the best hemodynamic profile. The aim of this study was to determine the prevalence of mismatch when using this prosthesis. METHODS: This study included 1,302 patients at 3 months postoperatively, 339 patients with a Trifecta prosthesis and 963 patients (the control group) with a Mitroflow aortic valve (Sorin Group Inc, Mitroflow Division, Vancouver, Canada)...
September 27, 2017: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/28889087/self-expanding-transcatheter-aortic-valve-implantation-for-degenerated-small-mitroflow-bioprosthesis-early-and-midterm-outcomes
#4
Marianna Adamo, Claudia Fiorina, Salvatore Curello, Giuliano Chizzola, Elena Pezzotti, Emanuele Gavazzi, Luca Branca, Ermanna Chiari, Filippo Quinzani, Michele Rinaldi, Marco Metra, Federica Ettori
AIMS: The aim of this study was to report clinical outcomes of self-expanding transcatheter aortic valve implantation (TAVI) for failed small Mitroflow (MF) bioprostheses. METHODS AND RESULTS: Between January 2013 and July 2016, 15 symptomatic patients (NYHA Class ≥III) with degenerated small MF (≤23 mm) underwent CoreValve (CV) or Evolut R (EvR) implantation due to high/prohibitive risk for surgical redo. The MF size was 19 or 21 mm (off-label in Europe) in eight patients...
September 10, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28838100/long-term-results-of-the-mitroflow-aortic-pericardial-bioprosthesis-in-over-800-patients-limited-durability-and-mechanisms-of-dysfunction
#5
Fabio Ius, Julia Schulz, Mazen Roumieh, Felix Fleissner, Issam Ismail, Igor Tudorache, Gregor Warnecke, Andreas Martens, Malakh Shrestha, Dietmar Boethig, Axel Haverich, Serghei Cebotari
OBJECTIVES: The Mitroflow aortic pericardial bioprosthesis was widely employed in the past. However, some authors have recently reported early structural valve deterioration (SVD) of the Mitroflow LA/LXA model. Thus, we reviewed our experience with the Mitroflow bioprosthesis and studied the risk factors for SVD and mortality. METHODS: Records of patients who underwent aortic valve replacement with a Mitroflow bioprosthesis between November 2005 and January 2015 were retrospectively evaluated with Kaplan-Meier, Cox-regression and multistate analysis...
August 1, 2017: European Journal of Cardio-thoracic Surgery
https://www.readbyqxmd.com/read/28698291/bioprosthetic-valve-fracture-improves-the-hemodynamic-results-of-valve-in-valve-transcatheter-aortic-valve-replacement
#6
Adnan K Chhatriwalla, Keith B Allen, John T Saxon, David J Cohen, Sanjeev Aggarwal, Anthony J Hart, Suzanne J Baron, Danny Dvir, A Michael Borkon
BACKGROUND: Valve-in-valve (VIV) transcatheter aortic valve replacement (TAVR) may be less effective in small surgical valves because of patient/prosthesis mismatch. Bioprosthetic valve fracture (BVF) using a high-pressure balloon can be performed to facilitate VIV TAVR. METHODS AND RESULTS: We report data from 20 consecutive clinical cases in which BVF was successfully performed before or after VIV TAVR by inflation of a high-pressure balloon positioned across the valve ring during rapid ventricular pacing...
July 2017: Circulation. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28691908/high-pressure-balloon-fracturing-of-small-dysfunctional-mitroflow-bioprostheses-facilitates-transcatheter-aortic-valve-in-valve-implantation
#7
Jens Erik Nielsen-Kudsk, Asger Andersen, Christian Juhl Therkelsen, Evald Høj Christensen, Kaare Troels Jensen, Lars Romer Krusell, Mariann Tang, Kim Allan Terp, Kaj-Erik Klaaborg, Jacob Raben Greisen, Bjarne Linde Nørgaard, Henning Rud Andersen
AIMS: Transcatheter valve-in-valve (VIV) implantation is usually discouraged in small surgical tissue valves. We report our first ten cases of fracturing small dysfunctional Mitroflow bioprostheses by high-pressure balloon dilatation to increase the internal diameter of the surgical valve before VIV (BF-VIV). METHODS AND RESULTS: BF-VIV was performed in 10 patients (mean age 84±4 years) with failing Mitroflow valves size 19 mm (n=3, threshold of fracture 15 atm) and 21 mm (n=7, threshold of fracture 13 atm)...
September 10, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28669505/bioprosthetic-valve-fracture-to-facilitate-transcatheter-valve-in-valve-implantation
#8
Keith B Allen, Adnan K Chhatriwalla, David J Cohen, John T Saxon, Sanjeev Aggarwal, Anthony Hart, Suzanne Baron, J Russell Davis, Alex F Pak, Danny Dvir, A Michael Borkon
BACKGROUND: Valve-in-valve transcatheter aortic valve replacement is less effective in small surgical bioprostheses. We evaluated the feasibility of bioprosthetic valve fracture with a high-pressure balloon to facilitate valve-in-valve transcatheter aortic valve replacement. METHODS: In vitro bench testing on aortic tissue valves was performed on 19-mm and 21-mm Mitroflow (Sorin, Milan, Italy), Magna and Magna Ease (Edwards Lifesciences, Irvine, CA), Trifecta and Biocor Epic (St...
November 2017: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/28548475/patterns-of-use-and-durability-for-the-mitroflow-aortic-valve-a-systematic-review-of-the-literature
#9
REVIEW
Theodor Fischlein, Steffen Pfeiffer, Vincenzo Bagnardi, Giuseppe Santarpino
INTRODUCTION: The aim of this study was to evaluate durability of Mitroflow and patterns of use compared with other aortic valves through a systematic review of the literature. EVIDENCE ACQUISITION: A total of 52 papers that included 33,630 patients met eligibility requirements that allowed summary statistical information to be determined regarding structural valve degeneration risk. EVIDENCE SYNTHESIS: Mitroflow has been disporportionately implanted in patients to be at higher risk for structural valve degeneration...
December 2017: Journal of Cardiovascular Surgery
https://www.readbyqxmd.com/read/28544842/transfemoral-valve-in-valve-in-a-degenerated-small-aortic-bioprosthesis-five-year-follow-up
#10
Stefano Salizzoni, Federico Conrotto, Mauro Rinaldi, Gian Paolo Ussia, Gaetana Ferraro, Mauro Giorgi, Maurizio D'Amico
A small-sized bioprosthesis can limit transcatheter valve-in-valve (V-in-V) implantations. The case is reported of a 91-year-old woman who had successfully undergone a V-in-V procedure with a 26 mm CoreValve in a previously implanted Mitroflow 19 mm valve. At the five-year follow up the prosthesis showed good echocardiographic function and the patient was alive and free from major symptoms. The patient died three months after the follow up examination at the age of 96 years. This case demonstrates the feasibility, with acceptable longterm functioning, of a V-in-V procedure involving a small bioprosthesis...
January 2017: Journal of Heart Valve Disease
https://www.readbyqxmd.com/read/28498900/mid-to-long-term-results-following-aortic-valve-replacement-using-the-mitroflow-xeno-pericardial-bioprosthesis-somewhat-different-views-from-2-high-volume-institutions
#11
Thierry Carrel
No abstract text is available yet for this article.
August 1, 2017: European Journal of Cardio-thoracic Surgery
https://www.readbyqxmd.com/read/28475560/hydrodynamic-and-geometric-behavior-of-two-pericardial-prostheses-implanted-in-small-aortic-roots
#12
Giordano Tasca, Gianfranco Beniamino Fiore, Paola Redaelli, Claudia Romagnoni, Alberto Redaelli, Amando Gamba, Carlo Antona, Riccardo Vismara
Hydrodynamic performance of stented bioprostheses is far below that of the native valve. One of the reasons is that the internal diameter of the prosthesis is usually smaller than that of the native valve. However, other valve characteristics are also important in generating the pressure drop. We aimed to assess, in an ex vivo pulsatile mock loop, the hydrodynamic behavior of two bioprostheses, Trifecta and Mitroflow, to ascertain which geometric terms are limiting factors in hydrodynamic performance. At stroke volumes between 30 and 60 ml, Trifecta showed lower pressure drop, energy dissipation and valve resistance, and greater effective orifice area...
May 4, 2017: ASAIO Journal: a Peer-reviewed Journal of the American Society for Artificial Internal Organs
https://www.readbyqxmd.com/read/28465144/real-structural-valve-deterioration-of-the-mitroflow-aortic-prosthesis-competing-risk-analysis
#13
Rocío Díaz, Daniel Hernández-Vaquero, Jacobo Silva, Isaac Pascual, Jesús M de la Hera, Víctor León, María Martín, Vicente Barriales, Santiago Colunga, Raquel Del Valle, César Morís
INTRODUCTION AND OBJECTIVES: The Mitroflow aortic prosthesis is a bovine pericardial bioprosthesis specially designed to increase the valve area in relation to its size. There is controversy regarding the pattern of structural valve deterioration (SVD). Our aim was to determine the cumulative incidence of SVD, risk factors influencing its occurrence, and its impact on mortality. METHODS: A total of 1028 patients were clinically and echocardiographically followed up...
May 2, 2017: Revista Española de Cardiología
https://www.readbyqxmd.com/read/28430883/ten-year-results-of-aortic-valve-replacement-with-first-generation-mitroflow-bioprosthesis-is-early-degeneration-a-structural-or-a-technical-issue
#14
Liesbeth Lootens, Jonas Verbeke, Thomas Martens, Tine Philipsen, Frank Caes, Yves Van Belleghem, Guido Van Nooten, Katrien François, Dirk De Bacquer, Thierry Bove
OBJECTIVES: Concerns have been raised about the durability of the first-generation Mitroflow aortic bioprosthesis (model 12 A-LX) due to the lack of anticalcification treatment. This study reflects a 10-year experience with this prosthesis for aortic valve replacement. METHODS: From June 2003 to May 2012, the Mitroflow prosthesis was used for aortic valve replacement in 510 patients, of whom only 467 with complete clinical follow-up were included for analysis. Study end-points were survival and incidence of structural valve degeneration (SVD)...
August 1, 2017: European Journal of Cardio-thoracic Surgery
https://www.readbyqxmd.com/read/28329233/corrigendum-to-the-italian-study-on-the-mitroflow-postoperative-results-isthmus-a-20-year-multicentre-evaluation-of-mitroflow-pericardial-bioprosthesis-eur-j-cardiothorac-surg-2011-39-18-26
#15
(no author information available yet)
No abstract text is available yet for this article.
April 1, 2017: European Journal of Cardio-thoracic Surgery
https://www.readbyqxmd.com/read/28129319/mini-bentall-an-interesting-approach-for-selected-patients
#16
Elisa Mikus, Antonio Micari, Simone Calvi, Maria Salomone, Marco Panzavolta, Marco Paris, Mauro Del Giglio
OBJECTIVE: Minimally invasive surgery through an upper hemisternotomy for aortic valve replacement has become the routine approach with excellent results. Actually, the same minimally invasive access is used for complex ascending aorta procedures only in few centers. We report our experience with minimally invasive approach for aortic valve and ascending aorta replacement using Bentall technique. METHODS: From January 2010 to November 2015, a total of 238 patients received ascending aorta and aortic valve replacement using Bentall De Bono procedure at our institution...
January 2017: Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery
https://www.readbyqxmd.com/read/28043449/stentless-vs-stented-aortic-valve-bioprostheses-in-the-small-aortic-root
#17
COMPARATIVE STUDY
Laurens W Wollersheim, Wilson W Li, Abdullah Kaya, Berto J Bouma, Antoine H Driessen, Wim J van Boven, Jan van der Meulen, Bas A de Mol
In patients with a small aortic root undergoing aortic valve replacement (AVR), the Freedom SOLO bioprosthesis may be the ideal prosthesis because of its stentless design and supra-annular implantation. This study investigated if the stentless Freedom SOLO has an advantage when compared with a stented bioprosthesis in patients with a small aortic root. From April 2005-July 2014, 269 consecutive patients underwent AVR with either a Freedom SOLO (n = 76) or Mitroflow (n = 193) bioprosthesis size 19mm or 21mm, respectively...
July 2016: Seminars in Thoracic and Cardiovascular Surgery
https://www.readbyqxmd.com/read/28040770/effect-of-bioprostheses-anti-calcification-treatment-comparative-follow-up-between-mitroflow-lx-and-magna-pericardial-xenografts-using-a-propensity-score-weighted-analysis
#18
COMPARATIVE STUDY
Arnau Blasco-Lucas, Eduard Permanyer, María-Llanos Pérez, Juan Manuel Gracia-Baena, Remedios Ríos, Kelly Casós, Manuel Galiñanes
Objectives: The efficacy of anti-calcification treatment of bioprosthetic heart valves remains unclear. The aim of this study was to compare the clinical outcomes between Mitroflow LX valve, without anti-calcification treatment, and the Carpentier-Edwards Perimount Magna (P-Magna), with anti-calcification treatment. Methods: Between 2005 and 2012, 625 consecutive patients underwent aortic valve replacement either with a Mitroflow LX ( n  = 329) or a P-Magna ( n  = 296)...
March 1, 2017: Interactive Cardiovascular and Thoracic Surgery
https://www.readbyqxmd.com/read/27986257/the-mitroflow-aortic-valve-a-past-present-and-future-illuminated
#19
EDITORIAL
Leora B Balsam, Abe DeAnda
No abstract text is available yet for this article.
January 2017: Journal of Thoracic and Cardiovascular Surgery
https://www.readbyqxmd.com/read/27776914/the-fate-of-small-size-pericardial-heart-valve-prostheses-in-an-older-patient-population
#20
Ruggero De Paulis, Salvatore D'Aleo, Alessandro Bellisario, Andrea Salica, Luca P Weltert, Raffaele Scaffa, Lorenzo Guerrieri Wolf, Daniele Maselli, Michele Di Mauro
BACKGROUND: Structural valve deterioration (SVD) is the Achilles' heel of bioprostheses. Its correlation with younger age is well known. In recent years we exclusively reserved use of small-size Mitroflow valve prostheses (LivaNova, London, United Kingdom) to an older patient population with small aortic annuli. This study aimed to assess the incidence of SVD and its effect on patient survival and need for reoperation. MATERIALS AND METHODS: Two hundred five patients (aged 75...
January 2017: Journal of Thoracic and Cardiovascular Surgery
keyword
keyword
50394
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"